News · Health

Tirzepatide and Semaglutide: Reading the Risks

By AWEI · AI-compiled · Published 2026-09-16 · 1 source · medvestnik.ru

Greater reported weight loss with tirzepatide comes with a safety signal that mixed study designs and limited follow-up complicate.

For adults weighing obesity treatment evidence, greater average weight loss and more reported serious adverse events create different questions, not a single answer. Medvestnik’s summary of a Clinical Obesity review associates tirzepatide with stronger weight reduction than semaglutide, alongside a safety signal. Reading the risks requires establishing which studies contributed to each result before deciding what the comparison means. Otherwise, an apparent ranking can conceal uncertainty about both the people studied and the events being counted.

Different outcomes, different evidence

Medvestnik reports that the review included 41,381 adults across three randomized trials and seven retrospective cohorts. Across ten studies, tirzepatide was associated with 4.28 percentage points greater weight reduction, with a 95% confidence interval of 3.28–5.28. Serious adverse events came from only three studies: 5.7% versus 2.9%, with a pooled risk ratio of 1.83 and a 95% confidence interval of 1.18–2.85. These estimates describe different evidence subsets. Placing them together is necessary, but does not create a matched calculation of individual benefit and harm.

That distinction changes the question from which medicine wins to what each endpoint establishes. Percentage points express a difference between percentage reductions; they are not interchangeable with a relative percentage advantage. Likewise, a pooled risk ratio summarizes a comparative association, while the reported event percentages describe observed proportions. Neither identifies whether a particular person would experience an event because of treatment. A serious event occurring during treatment is not automatically an event caused by the drug, even when a comparative signal deserves close scrutiny.

Why a safety ranking remains unresolved

Randomized trials and retrospective cohorts also answer questions under different constraints. Randomization is designed to reduce systematic differences between treatment groups, whereas retrospective comparisons may retain differences in who received each medicine. Medvestnik identifies residual confounding and substantial heterogeneity in some efficacy outcomes. Patient selection could therefore contribute to the apparent balance, while a genuine treatment-related effect remains another explanation. Differences in dosing or event detection are additional possibilities. The secondary account cannot apportion their contributions, and the mixture of study designs should remain visible beside the pooled results.

The reported follow-up of 24–72 weeks and varied weekly doses further limit interpretation. A comparison across those conditions does not settle outcomes at a particular dose or over several years. Medvestnik also reports an additional HbA1c reduction of 0.29 percentage points across five studies, with a 95% confidence interval of 0.14–0.44. This adds a metabolic endpoint, rather than resolving the safety question. Treatment discontinuation because of adverse events did not differ significantly, but that finding does not establish equivalent safety or explain the serious-event association.

Edelman’s Tipping Points 2026, published in 2026, supplies a narrow communication lens: make evidence quality, benefits and uncertainty understandable before asking audiences to accept a health claim. Its material is a communications-oriented synthesis for organizational leaders, drawing on varied markets and health, food and beauty examples, including the Netherlands. It is not a clinical comparison or a single documented patient study. Its 2026 outlook neither adjudicates these medicines nor demonstrates that its recommended communication improves decisions. Here, it supports clearer explanation, not medical authority.

The evidence that would change the interpretation

A useful inquiry would examine study-level event categories, comparable dosing and consistent definitions before collapsing the findings into an overall treatment ranking. If longer randomized comparisons reproduced the safety difference under comparable conditions, a treatment-related explanation would strengthen. If the difference were concentrated in retrospective cohorts and diminished with better adjustment, confounding would become more plausible. Those possibilities make the signal investigable without treating it as either proven causation or something to dismiss. This is a framework for reading evidence, not a recommendation to choose or delay treatment.

Patients bear potential benefits and harms together, while pooled averages cannot identify their individual net benefit. The broader issue is how medical comparisons translate multiple outcomes into an apparently simple hierarchy. In this case, the available account supports greater average weight reduction and further investigation of a reported safety association. It leaves longer-term weight maintenance, uncommon events and causal explanations unresolved. Progress comes from defining those missing pieces precisely, rather than asking a single headline to settle which treatment is universally preferable.

All newsNews archive